Biocon gets approval for anti-CD-6 psoriasis biologic
This article was originally published in Scrip
Executive Summary
As Biocon receives marketing authorization in India for its anti-CD6 monoclonal antibody, itolizumab, for chronic plaque psoriasis, analysts suggest that large markets like the US, EU and Japan hold significant promise for the product.